Type-II Diabetes Clinical Trial
Official title:
Evaluating the Effect and Safety of Postbiotic MBS and Metformin Combination on Gut Microbiota and Symptom in Patients With Diabetes
| Verified date | January 2023 |
| Source | Microbio Co Ltd |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary objective is to evaluate the effect of MBS treatment in human subjects, and to validate its impact on intestinal flora and diabetes symptoms on diabetic patients undertaking metformin. The scientific data collected will be referenced for future product development.
| Status | Completed |
| Enrollment | 14 |
| Est. completion date | September 23, 2022 |
| Est. primary completion date | June 30, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years to 70 Years |
| Eligibility | Inclusion Criteria: 1. Male or female subject who aged from 20 to 70. 2. BMI in between 18.5 and 35 kg/m2 inclusively. 3. Fasting blood sugar = 126 mg/dL, and confirmed diagnosis of type-II diabetes. 4. 30 days prior to the screening visit (V1), HbA1c is steadily maintained in between 7-10% by medication. 5. Prior to the screening visit (V1), subjects have been regularly taken 500-200 mg/day for at least 90 days. Exclusion Criteria: 1. Pregnant or breastfeeding women or female subjects plan to enter pregnancy during study period. 2. Subjects who are allergic to soy or products containing it. 3. At investigator's discretion, subjects are unlikely to comply with study procedures due to a history of alcohol or drug addiction. 4. Subjects on vegetarian diet or other special diets (eg. Ketogenic or gluten-free diets). 5. Subjects have ongoing participation in another clinical trial that involves the use of investigational drugs, medical devices, dietary supplements, and/or cosmetics. 6. Subject with impaired renal function confirmed by Serum Total Bilirubin = 1.5 upper limit of normal [ULN], Aspartate Transaminase/ Alanine Transaminase (AST/ALT) = 2 ULN, Creatinine = 2 ULN or eGFR <60 mL/min/1.73 m^2. 7. Subjects who have been diagnosed with malignant tumors within five (5) years before the screening visit (V1) with exception to subjects with topical cancer but show significant recovery following investigator's assessment, such as basal or squamous cell skin cancer, superficial bladder cancer, or prostate or cervix or carcinoma in situ of the breast. 8. 30 days prior to screening visit (V1), subjects have taken antibiotics, synthetic drugs (Sulfonamides, Fluoroquinolone, etc.), anti-fungal or anti-viral medication but not limited to topical forms for use in skin application. 9. Within 14 days prior to screening visit (V1), subjects have taken products or supplements that contain probiotics or prebiotics. 10. Within 14 days prior to screening visit (V1), subjects experience diarrhea caused by gastrointestinal infection (3 times of watery stool within 24 hours). 11. Within14 days prior to screening visit (V1), subjects have taken steroids, immunosuppressant, and/or inflammatory medicines. 12. Subjects took or intend to take medications other than metformin that may affect intestinal flora within 30 days prior to screening visit, during screening period or whole trial period. Examples of this kind of medication include DPP-4 inhibitors, GLP-1 receptor agonists, acarbose, hypoglycemic sulfonamides, thiazolidinediones, SGLT2 inhibitors, and insulin. |
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | Microbio Investigative Site | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| Microbio Co Ltd |
Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Post-treatment changes of intestinal flora | Post-treatment changes from baseline in microbial composition, abundance, variation of subject's intestinal flora at 4, 8, 12 weeks. | 4, 8,12 weeks post-treatment | |
| Secondary | Post-treatment changes from baseline in fasting plasma glucose at 12 weeks | 12 weeks post-treatment | ||
| Secondary | Post-treatment changes from baseline in HbA1c at 12 weeks | 12 weeks post-treatment | ||
| Secondary | Post-treatment changes from baseline in HOMA-IR at 12 weeks | 12 weeks post-treatment | ||
| Secondary | Post-treatment changes from baseline in blood lipids composition at 12 weeks | Changes of triglyceride, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) | 12 weeks post-treatment | |
| Secondary | Post-treatment changes from baseline in immune factors at 12 weeks | Changes of CRP, IL6, TNF-a expression | 12 weeks post-treatment | |
| Secondary | Incidence of treatment-emergent adverse events(TEAE) | 12 weeks post-treatment |